A new study published by University of Kentucky Markey Cancer Center researchers suggests that the common steroid betamethasone could be used to reduce unwanted side effects of radiation treatments for prostate cancer.

Getty Images


August 15, 2022 — A new study published by University of Kentucky Markey Cancer Center researchers suggests that the common steroid betamethasone could be used to reduce unwanted side effects of radiation treatments for prostate cancer.   

The research was published in the International Journal of Molecular Sciences June 8. 

The lab study led by Luksana Chaiswing, Ph.D., assistant professor in the UK College of Medicine’s Department of Toxicology and Cancer Biology, is the first to demonstrate that betamethasone protects normal prostate cells from injury induced by radiation therapy, while making the cancer cells more susceptible to the treatment. 

Prostate cancer is the second leading cause of cancer deaths among men in the U.S. While radiation therapy is important to control the growth of prostate cancer, it presents a significant risk of increasing unwanted side effects, including injury to normal tissues. 

“New therapies aimed at protecting against normal tissue injury while also increasing radiation therapy effectiveness are urgently needed,” Chaiswing said. “The development of such approaches would have a major impact on prostate cancer control and the quality of life of patients.” 

The team screened around 700 Food and Drug Administration-approved drugs for properties including protecting non-cancer cells against radiation therapy induced cytotoxicity, killing prostate cancer cells and increasing hydrogen peroxide levels in both cancer and non-cancer cells. 

Betamethasone, a corticosteroid that is approved for treatment of inflammation and cancer of the hematopoietic system, was one of the top five drugs with all of the desired properties. 

Betamethasone increases hydrogen peroxide levels, which activates a protective protein called “RelB” in normal, non-cancerous prostate cells. 

“The outcome of this project could lead to a new anticancer regimen that improves the efficacy of radiation therapy by sensitizing tumor tissue to radiation while simultaneously protecting normal tissue from radiation-induced side effects, which could lead to improved quality of life for cancer survivors,” Chaiswing said. 

For more information: https://www.uky.edu/ 


Related Content

News | Radiation Therapy

May 23, 2024 — RaySearch Laboratories AB and C-RAD announced a collaboration agreement, aiming at jointly developing ...

Time May 23, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, recently ...

Time May 22, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 21, 2024 — RaySearch Laboratories AB announced that the oncology information system RayCare* 2024A has been ...

Time May 21, 2024
arrow
News | Proton Therapy

May 21, 2024 — IBA, a world leader in particle accelerator technology, announced that it has signed a contract with the ...

Time May 21, 2024
arrow
News | Radiology Business

May 20, 2024 — Associated Medical Professionals of NY (A.M.P.) announced that internationally recognized radiation ...

Time May 20, 2024
arrow
News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Radiation Therapy

May 16, 2024 — Today marks a significant milestone in cancer care with the introduction of bipartisan federal ...

Time May 16, 2024
arrow
News | FDA

May 14, 2024 — Indica Labs, the leading provider of digital pathology solutions, announced today that it received FDA ...

Time May 14, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Artificial Intelligence

May 14, 2024 — Elekta announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high ...

Time May 14, 2024
arrow
Subscribe Now